These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6148118)

  • 41. Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.
    Meszaros K; Lenzinger E; Hornik K; Schönbeck G; Hatzinger R; Langer G; Sieghart W; Aschauer HN
    Neuropsychobiology; 1997; 36(2):69-72. PubMed ID: 9267855
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A double-blind comparison of raclopride and haloperidol in the acute phase of schizophrenia. The British Isles Raclopride Study Group.
    Acta Psychiatr Scand; 1992 Nov; 86(5):391-8. PubMed ID: 1485530
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A double-blind comparative multicentre study of controlled-release remoxipride, immediate-release remoxipride and haloperidol in schizophrenia.
    Hebenstreit GF; Laux G; Schubert H; Beckmann H; Amman J; Bunse J; Eikmeier G; Geretsegger C; Kanitz RD; Kanzow WT
    Pharmacopsychiatry; 1991 Sep; 24(5):153-8. PubMed ID: 1685572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A controlled trial of amantadine in drug-induced extrapyramidal disorders.
    DiMascio A; Bernardo DL; Greenblatt DJ; Marder JE
    Arch Gen Psychiatry; 1976 May; 33(5):599-602. PubMed ID: 5066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double-blind, placebo-controlled trial.
    Borison RL; Sinha D; Haverstock S; McLarnon MC; Diamond BI
    Psychopharmacol Bull; 1989; 25(2):190-3. PubMed ID: 2574893
    [No Abstract]   [Full Text] [Related]  

  • 46. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB
    J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Extrapyramidal side effects are unacceptable.
    Kane JM
    Eur Neuropsychopharmacol; 2001 Oct; 11 Suppl 4():S397-403. PubMed ID: 11587887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical predictors of schizophrenic patient response to neuroleptics.
    Korínková V
    Act Nerv Super (Praha); 1989 Jun; 31(2):115-6. PubMed ID: 2572131
    [No Abstract]   [Full Text] [Related]  

  • 49. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 50. Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial.
    Fleischhacker WW; Barnas C; Stuppäck CH; Unterweger B; Miller C; Hinterhuber H
    Psychopharmacol Bull; 1989; 25(1):97-100. PubMed ID: 2570438
    [No Abstract]   [Full Text] [Related]  

  • 51. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
    Meltzer HY; Elkis H; Vanover K; Weiner DM; van Kammen DP; Peters P; Hacksell U
    Schizophr Res; 2012 Nov; 141(2-3):144-52. PubMed ID: 22954754
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reversal of rabbit syndrome with olanzapine.
    Damodaran SS; Thankamma JK
    Aust N Z J Psychiatry; 2000 Feb; 34(1):172-3. PubMed ID: 11185940
    [No Abstract]   [Full Text] [Related]  

  • 54. The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia.
    Cohen JD; Van Putten T; Marder S; Berger PA; Stahl SM
    J Clin Psychopharmacol; 1987 Oct; 7(5):324-9. PubMed ID: 2890671
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
    Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
    J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study.
    Zhang ZJ; Kang WH; Li Q; Wang XY; Yao SM; Ma AQ
    Schizophr Res; 2006 Dec; 88(1-3):102-10. PubMed ID: 16959472
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
    Nasrallah HA; Brecher M; Paulsson B
    Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.
    Purdon SE; Woodward N; Lindborg SR; Stip E
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):390-7. PubMed ID: 12827347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.